729 related articles for article (PubMed ID: 28426622)
1. CHANGES IN CENTRAL CHOROIDAL THICKNESS AFTER TREATMENT OF DIABETIC MACULAR EDEMA WITH INTRAVITREAL BEVACIZUMAB CORRELATION WITH CENTRAL MACULAR THICKNESS AND BEST-CORRECTED VISUAL ACUITY.
Nourinia R; Ahmadieh H; Nekoei E; Malekifar P; Tofighi Z
Retina; 2018 May; 38(5):970-975. PubMed ID: 28426622
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema.
Solaiman KA; Diab MM; Abo-Elenin M
Retina; 2010; 30(10):1638-45. PubMed ID: 20838357
[TBL] [Abstract][Full Text] [Related]
3. Changes in choroidal thickness after anti-vascular endothelial growth factor treatment of diabetic macular edema, real-life data, 2-year results.
Savur F; Kaldırım H; Atalay K; Korkmaz Ş
Cutan Ocul Toxicol; 2021 Dec; 40(4):326-331. PubMed ID: 34275395
[TBL] [Abstract][Full Text] [Related]
4. Anatomical and visual outcome of intravitreal bevacizumab (Avastin) in patients with diabetic macular edema.
Vyas S; Thapa R; Bajimaya S; Pradhan E; Paudyal G
Nepal J Ophthalmol; 2016 Jan; 8(15):54-61. PubMed ID: 28242886
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal injection of a Rho-kinase inhibitor (fasudil) combined with bevacizumab versus bevacizumab monotherapy for diabetic macular oedema: a pilot randomised clinical trial.
Ahmadieh H; Nourinia R; Hafezi-Moghadam A; Sabbaghi H; Nakao S; Zandi S; Yaseri M; Tofighi Z; Akbarian S
Br J Ophthalmol; 2019 Jul; 103(7):922-927. PubMed ID: 30150280
[TBL] [Abstract][Full Text] [Related]
6. Subfoveal choroidal thickness changes after intravitreal bevacizumab injection for neovascular age-related macular degeneration and diabetic macular edema.
Ünlü C; Erdogan G; Gunay BO; Kardes E; Akcay BI; Ergin A
Int Ophthalmol; 2017 Feb; 37(1):147-158. PubMed ID: 27154721
[TBL] [Abstract][Full Text] [Related]
7. Phacoemulsification with intravitreal bevacizumab and triamcinolone acetonide injection in diabetic patients with clinically significant macular edema and cataract.
Akinci A; Muftuoglu O; Altınsoy A; Ozkılıc E
Retina; 2011 Apr; 31(4):755-8. PubMed ID: 21124251
[TBL] [Abstract][Full Text] [Related]
8. Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months.
Arevalo JF; Sanchez JG; Wu L; Maia M; Alezzandrini AA; Brito M; Bonafonte S; Lujan S; Diaz-Llopis M; Restrepo N; Rodríguez FJ; Udaondo-Mirete P;
Ophthalmology; 2009 Aug; 116(8):1488-97, 1497.e1. PubMed ID: 19545900
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal Diclofenac plus Bevacizumab versus Bevacizumab alone in treatment-naive diabetic macular edema: a randomized double-blind clinical trial.
Ghanbari H; Kianersi F; Sonbolestan SA; Abtahi MA; Akbari M; Abtahi ZA; Abtahi SH
Int Ophthalmol; 2017 Aug; 37(4):867-874. PubMed ID: 27624173
[TBL] [Abstract][Full Text] [Related]
10. Correlation of Macular Thickness and Visual Acuity in DME Treated by Two Doses of Intravitreal Ziv-Aflibercept Versus Bevacizumab: Analysis of a Randomized, Three-Armed Clinical Trial.
Jabbarpoor Bonyadi MH; Baghi A; Ramezani A; Yaseri M; Soheilian M
Ophthalmic Surg Lasers Imaging Retina; 2019 Nov; 50(11):684-690. PubMed ID: 31755967
[TBL] [Abstract][Full Text] [Related]
11. Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.
Bahrami B; Hong T; Zhu M; Schlub TE; Chang A
Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1133-1140. PubMed ID: 28238195
[TBL] [Abstract][Full Text] [Related]
12. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study.
Gillies MC; Lim LL; Campain A; Quin GJ; Salem W; Li J; Goodwin S; Aroney C; McAllister IL; Fraser-Bell S
Ophthalmology; 2014 Dec; 121(12):2473-81. PubMed ID: 25155371
[TBL] [Abstract][Full Text] [Related]
13. AFLIBERCEPT FOR PERSISTENT DIABETIC MACULAR EDEMA: Forty-Eight-Week Outcomes.
Bahrami B; Hong T; Schlub TE; Chang AA
Retina; 2019 Jan; 39(1):61-68. PubMed ID: 30015767
[TBL] [Abstract][Full Text] [Related]
14. Functional and anatomic response of the retina and the choroid to intravitreal bevacizumab for macular edema.
Forte R; Cennamo G; Breve MA; Vecchio EC; de Crecchio G
J Ocul Pharmacol Ther; 2012 Feb; 28(1):69-75. PubMed ID: 22059904
[TBL] [Abstract][Full Text] [Related]
15. Effect of intravitreal dexamethasone implant on retinal and choroidal thickness in refractory diabetic macular oedema after multiple anti-VEGF injections.
Kim M; Cho YJ; Lee CH; Lee SC
Eye (Lond); 2016 May; 30(5):718-25. PubMed ID: 26939558
[TBL] [Abstract][Full Text] [Related]
16. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab versus triamcinolone for persistent diabetic macular edema: a randomized clinical trial.
Rodrigues MW; Cardillo JA; Messias A; Siqueira RC; Scott IU; Jorge R
Graefes Arch Clin Exp Ophthalmol; 2020 Mar; 258(3):479-490. PubMed ID: 31873786
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal bevacizumab for diabetic macular oedema: 5-year results of the Pan-American Collaborative Retina Study group.
Arevalo JF; Lasave AF; Wu L; Acon D; Farah ME; Gallego-Pinazo R; Alezzandrini AA; Fortuna V; Quiroz-Mercado H; Salcedo-Villanueva G; Maia M; Serrano M; Rojas S;
Br J Ophthalmol; 2016 Dec; 100(12):1605-1610. PubMed ID: 26912377
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal bevacizumab alone or combined with 1 mg triamcinolone in diabetic macular edema: a randomized clinical trial.
Riazi-Esfahani M; Riazi-Esfahani H; Ahmadraji A; Karkhaneh R; Mahmoudi A; Roohipoor R; Ghasemi F; Yaseri M
Int Ophthalmol; 2018 Apr; 38(2):585-598. PubMed ID: 28349504
[TBL] [Abstract][Full Text] [Related]
20. Phacoemulsification with intravitreal bevacizumab injection in diabetic patients with macular edema and cataract.
Akinci A; Batman C; Ozkilic E; Altinsoy A
Retina; 2009; 29(10):1432-5. PubMed ID: 19898181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]